Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On February 18, 2026, Aptevo Therapeutics Inc. (the "Company") held its Special Meeting of Stockholders (the "Special Meeting"), at which a quorum was present. Stockholders considered three proposals outlined below, each of which is described in more detail in the Company's definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission on January 26, 2026 (the "Proxy Statement"). The final voting results with respect to each of the proposals acted upon at the 2026 Special Meeting are set forth below.

Proposal 1: Approval of the Company's Amended and Restated Certificate of Incorporation

An amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to make certain technical and administrative changes was not approved based on the following:

Proposal 2: Approval of the stock issuance under the Standby Equity Purchase Agreement ("SEPA") with YA II PN, Ltd. ("Yorkville")

The issuance of more than 19.99% of the Company's issued and outstanding common stock as of January 8, 2026 pursuant to the SEPA with Yorkville, pursuant to Nasdaq Listing Rules 5635(d) and 5635(b) was approved based on the following:

Proposal 3: Authorization to adjourn the Special Meeting

The authorization to adjourn the Special Meeting to a later date, if necessary or appropriate, was approved based on the following votes: